Loading…

Loading grant details…

Active HORIZON European Commission

Multilevel inflammatory regulation in cardiometabolic disease


Funder European Commission
Recipient Organization Stichting Amsterdam Umc
Country Netherlands
Start Date Feb 01, 2024
End Date Jan 31, 2028
Duration 1,460 days
Number of Grantees 15
Roles Associated Partner; Participant; Coordinator
Data Source European Commission
Grant ID 101119370
Grant Description

The benefit of targeting inflammatory pathways in cardiometabolic disease on top of traditional healthcare and medication is evident from recent clinical studies.

However, generalized blocking of inflammation also impacts on patients’ defense against infections and other immune-associated pathologies, such as cancer. Clearly, more precise interventions that target disease-specific cellular subsets and mechanisms are eagerly awaited.

MIRACLE’s focus on innovation is to pave the way to precision medicine by deploying and valorizing current technological breakthroughs for a detailed definition and targeting of cardiometabolic disease-associated and causative cellular subsets.

MIRACLE is inspired by latest advances in single cell biology, multi-omics analysis and newest insights in macrophage biology.

These advances revealed heterogeneous and dynamic accumulation of (immune) cell populations in tissues that associate with disease initiation, development and particularly clinical outcome, a notion that has immense implications on our view of chronic inflammatory diseases and their treatment. Unique know-how is ready to be transferred to highly talented fellows.

In MIRACLE, twelve young scientists will receive tailored training that enables them to study local and environmental factors that drive cardiometabolic inflammation as well as develop strategies to suppress them, via the integrated use of cutting-edge single cell, spatial mapping, computational and disease modeling approaches.

Moreover, they will be able to develop and polish skills in translational science by working with biotech- and pharma experts and clinicians pledging clinically actionable outcomes.

The combination of high-level science with top-notch infrastructures, resources, and solid data places MIRACLE at the forefront to move single cell biology towards cardiometabolic (precision) medicine and foster the scientists of tomorrow.

All Grantees

Astrazeneca Ab; Universitaet Bern; Universiteit Maastricht; Biomimx Srl; Rheinische Friedrich-Wilhelms-Universitat Bonn; Stichting Amsterdam Umc; Politecnico Di Milano; Nanostring Technologies Inc; Universite de Lille; Science Matters; Katholieke Universiteit Leuven; Ita-Suomen Yliopisto; University of San Diego; Universiteit Van Amsterdam; European Atherosclerosis Society

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant